Background: Lipoprotein(a) is an atherogenic particle and cardiovascular risk factor. 1 Some guidelines recommend testing at least once in the lifetime of an individual, yet testing rates remain low. 2,3 Limited test availability may be a contributing factor to this. In this study, the analytical performance of a point-of-care lipoprotein(a) measurement device (iProtin) was compared with two laboratory assay platforms (Randox and Roche).
Bachmeier et al. (Sun,) studied this question.